Generic Product News (July 2017)

Publication
Article
Pharmacy TimesJuly 2017 Digestive Health
Volume 83
Issue 7

Read about the new generic products featured in July.

MARKETED BY: Teva Pharmaceutical Industries Ltd

COMPARE TO: Vytorin (Merck)

INDICATION: Teva has launched its generic version of Vytorin (ezetimibe and simvastatin) tablets in the United States. Ezetimibe and simvastatin tablets are indicated for use alongside diet to decrease low-density lipoprotein cholesterol, increase high-density lipoprotein cholesterol, and lower the level of fat in the blood.

DOSAGE FORM: Tablets: 10 mg/10 mg, 10 mg/20 mg, 10 mg/40 mg, and 10 mg/80 mg

FOR MORE INFORMATION: tevapharm.com

MARKETED BY: Solco Healthcare

COMPARE TO: Benicar-HCT (Daiichi-Sankyo)

INDICATION: Solco Healthcare has launched its generic version of Benicar-HCT (olmesartan medoxomil and hydrochlorothiazide) tablets. Olmesartan medoxomil and hydrochlorothiazide tablets are indicated for the treatment of hypertension to lower blood pressure; however, the drug should not be used for the initial therapy of hypertension.

DOSAGE FORM: Tablets: 20 mg/12.5 mg, 40 mg/12.5 mg, and 40 mg/25 mg

FOR MORE INFORMATION: solcohealthcare.com

MARKETED BY: Teva Pharmaceutical Industries Ltd

COMPARE TO: Glumetza (Salix Pharmaceuticals)

INDICATION: Teva has announced the launch of its generic version of Glumetza tablets in the United States. Metformin hydrochloride extendedrelease tablets are used with diet and exercise to help control high blood sugar in adults with type 2 diabetes.

DOSAGE FORM: Tablets: 500 mg and 1000 mg

FOR MORE INFORMATION: tevapharm.com

MARKETED BY: Aurobindo

COMPARE TO: Azor (Daiichi Sankyo)

INDICATION: The FDA has approved Aurobindo’s generic version of Azor. Amlodipine and olmesartan medoxomil tablets are indicated for the treatment of hypertension.

DOSAGE FORM: Tablets: 5 mg/20 mg, 5 mg/40 mg, 10 mg/20 mg, and 10 mg/40 mg

FOR MORE INFORMATION: aurobindousa.com

Related Videos
Practice Pearl #1 Active Surveillance vs Treatment in Patients with NETs
© 2024 MJH Life Sciences

All rights reserved.